Pharmacologic treatment of gastroparesis: What is (still) on the horizon?

被引:3
|
作者
Schweckendiek, D. [1 ]
Pohl, D. [1 ]
机构
[1] Univ Hosp Zurich Switzerland, Dept Gastroenterol & Hepatol, Raemistr 100, CH-8091 Zurich, Switzerland
关键词
DIABETIC GASTROPARESIS;
D O I
10.1016/j.coph.2023.102395
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an update on possible future treatment options.
引用
收藏
页数:6
相关论文
共 50 条